Trial Profile
Open-labeled, Uncontrolled, Single-arm Pilot Study to Evaluate Cellular Immunotherapy Using CD19-targeted Chimeric Antigen Receptor Engineered T Cells in Patients With Relapsed or Refractory CD19+ B Cell Leukemia
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs GB 5005 (Primary) ; Cyclophosphamide; Fludarabine
- Indications B-cell leukaemia
- Focus Adverse reactions; Therapeutic Use
- Sponsors Shanghai Genechem
- 04 May 2016 New trial record